摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-((2-(4-(1-methylpiperidin-4-yl)phenyl)pyridin-4-yl)oxy)pyridin-2-amine

中文名称
——
中文别名
——
英文名称
5-((2-(4-(1-methylpiperidin-4-yl)phenyl)pyridin-4-yl)oxy)pyridin-2-amine
英文别名
5-((2-(4-(1-Methylpiperidin-4-yl)phenyl)pyridin-4-yl)oxy)pyridin-2-amine;5-[2-[4-(1-methylpiperidin-4-yl)phenyl]pyridin-4-yl]oxypyridin-2-amine
5-((2-(4-(1-methylpiperidin-4-yl)phenyl)pyridin-4-yl)oxy)pyridin-2-amine化学式
CAS
——
化学式
C22H24N4O
mdl
——
分子量
360.459
InChiKey
UKIBQKIJWBUWBL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    64.3
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
    申请人:Deciphera Pharmaceuticals, LLC
    公开号:US09382228B2
    公开(公告)日:2016-07-05
    Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    本文描述了I式化合物,通过抑制c-FMS(CSF-1R)、c-KIT和/或PDGFR激酶,可在治疗癌症、自身免疫性疾病和代谢性骨疾病方面发挥作用。这些化合物还可用于治疗其他由c-FMS、c-KIT或PDGFR激酶介导的哺乳动物疾病。
  • US20140275080A1
    申请人:——
    公开号:——
    公开(公告)日:——
  • N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
    申请人:Deciphera Pharmaceuticals, LLC
    公开号:EP2968287B1
    公开(公告)日:2020-06-24
  • US9382228B2
    申请人:——
    公开号:US9382228B2
    公开(公告)日:2016-07-05
  • [EN] N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES<br/>[FR] N-ACYL-N'-(PYRIDIN-2-YL)URÉES ET ANALOGUES MONTRANT DES ACTIVITÉS ANTICANCÉREUSES ET ANTIPROLIFÉRATIVES
    申请人:DECIPHERA PHARMACEUTICALS LLC
    公开号:WO2014145028A2
    公开(公告)日:2014-09-18
    Described are compounds of Formula I, which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c- FMS, c-KIT, or PDGFR kinases.
查看更多